Bio-Thera Solutions Ltd - Asset Resilience Ratio
Bio-Thera Solutions Ltd (688177) has an Asset Resilience Ratio of 4.09% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 688177 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Bio-Thera Solutions Ltd's Asset Resilience Ratio has changed over time. See 688177 equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bio-Thera Solutions Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Bio-Thera Solutions Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥90.22 Million | 4.09% |
| Total Liquid Assets | CN¥90.22 Million | 4.09% |
Asset Resilience Insights
- Limited Liquidity: Bio-Thera Solutions Ltd maintains only 4.09% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bio-Thera Solutions Ltd Industry Peers by Asset Resilience Ratio
Compare Bio-Thera Solutions Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Wuhan Hvsen Biotechnology Co Ltd
SHE:300871 |
Biotechnology | 6.52% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Annual Asset Resilience Ratio for Bio-Thera Solutions Ltd (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Bio-Thera Solutions Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.09% | CN¥90.22 Million ≈ $13.20 Million |
CN¥2.21 Billion ≈ $322.74 Million |
-10.38pp |
| 2023-12-31 | 14.47% | CN¥331.03 Million ≈ $48.44 Million |
CN¥2.29 Billion ≈ $334.67 Million |
-14.42pp |
| 2022-12-31 | 28.90% | CN¥629.89 Million ≈ $92.17 Million |
CN¥2.18 Billion ≈ $318.96 Million |
+5.87pp |
| 2021-12-31 | 23.03% | CN¥602.83 Million ≈ $88.21 Million |
CN¥2.62 Billion ≈ $383.06 Million |
-16.91pp |
| 2020-12-31 | 39.94% | CN¥955.77 Million ≈ $139.86 Million |
CN¥2.39 Billion ≈ $350.19 Million |
-- |
About Bio-Thera Solutions Ltd
Bio-Thera Solutions, Ltd., a biopharmaceutical company, researches and develops novel therapeutics for the treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe unmet medical needs in China and internationally. It offers QLETLI for the treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; POBEVCY to treat patients with metast… Read more